Delcath Systems, Inc. $DCTH Holdings Boosted by Propel Bio Management LLC

Propel Bio Management LLC grew its holdings in Delcath Systems, Inc. (NASDAQ:DCTH) by 94.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 438,509 shares of the company’s stock after purchasing an additional 212,457 shares during the period. Delcath Systems makes up 4.7% of Propel Bio Management LLC’s portfolio, making the stock its 8th biggest position. Propel Bio Management LLC’s holdings in Delcath Systems were worth $4,714,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of DCTH. Fox Run Management L.L.C. purchased a new position in shares of Delcath Systems during the third quarter valued at $294,000. Vanguard Group Inc. boosted its position in Delcath Systems by 2.9% during the 3rd quarter. Vanguard Group Inc. now owns 1,657,428 shares of the company’s stock worth $17,817,000 after acquiring an additional 46,693 shares during the period. Cibc World Market Inc. boosted its position in Delcath Systems by 21.8% during the 3rd quarter. Cibc World Market Inc. now owns 178,510 shares of the company’s stock worth $1,919,000 after acquiring an additional 31,900 shares during the period. Simplify Asset Management Inc. grew its stake in Delcath Systems by 144.9% during the 3rd quarter. Simplify Asset Management Inc. now owns 261,126 shares of the company’s stock valued at $2,807,000 after acquiring an additional 154,497 shares in the last quarter. Finally, Capital Advisors Wealth Management LLC grew its stake in Delcath Systems by 12.5% during the 3rd quarter. Capital Advisors Wealth Management LLC now owns 85,500 shares of the company’s stock valued at $919,000 after acquiring an additional 9,500 shares in the last quarter. Institutional investors and hedge funds own 61.12% of the company’s stock.

Delcath Systems Stock Up 7.3%

Shares of DCTH opened at $9.23 on Thursday. The company’s fifty day moving average is $9.91 and its 200-day moving average is $10.16. Delcath Systems, Inc. has a 12 month low of $8.12 and a 12 month high of $18.23. The firm has a market cap of $320.74 million, a price-to-earnings ratio of 131.86 and a beta of 0.38.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. The business had revenue of $20.73 million during the quarter, compared to analyst estimates of $20.35 million. Delcath Systems had a net margin of 3.17% and a return on equity of 2.63%. As a group, research analysts predict that Delcath Systems, Inc. will post -0.79 earnings per share for the current fiscal year.

Delcath Systems announced that its board has initiated a stock repurchase program on Thursday, November 20th that authorizes the company to buyback $25.00 million in shares. This buyback authorization authorizes the company to buy up to 8.6% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Stephens reduced their price target on shares of Delcath Systems from $25.00 to $18.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Wall Street Zen lowered shares of Delcath Systems from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Delcath Systems in a research report on Friday, January 9th. Weiss Ratings reissued a “sell (d+)” rating on shares of Delcath Systems in a research note on Monday, December 29th. Finally, Evercore set a $27.00 price target on shares of Delcath Systems in a report on Thursday, February 26th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

Delcath Systems News Summary

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Publication of CHOPIN Phase 2 trial in The Lancet Oncology — The full, investigator‑initiated CHOPIN randomized Phase 2 results led by Prof. Ellen Kapiteijn were published, increasing clinical visibility and credibility for Delcath’s liver‑directed chemotherapy platform; this type of high‑profile peer‑reviewed publication can support investor confidence and future regulatory/commercial discussions. Article Title Business Wire Release
• Neutral Sentiment: HC Wainwright maintains a Buy rating and a $30 price target — the firm continues to show long‑term conviction even as it revises near‑term numbers, which may temper negative reactions relative to a full downgrade.
• Neutral Sentiment: Long‑range forecasts mixed — HC Wainwright published multi‑year model estimates (including a new FY2030 EPS projection), showing a path to profitability further out; these farther‑out estimates are informative but less likely to move the stock as much as near‑term revisions.
• Neutral Sentiment: Short interest report shows no meaningful data change — the reported short interest figures appear to be zero/erroneous and do not indicate increased short pressure at this time.
• Negative Sentiment: Multiple downward EPS revisions from HC Wainwright — the analyst cut Q1–Q4 2026 and FY2026 estimates significantly (examples: Q1 from $0.13 to ($0.01), Q2 from $0.08 to ($0.15), Q3 from $0.10 to ($0.42), and FY2026 from $0.58 to ($0.86)), and lowered FY2027‑FY2029/FY2028/FY2029 forecasts as well. Those near‑term cuts increase uncertainty about upcoming quarters and could limit upside despite the trial publication.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.